A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1
420
about 2.9 years
18+
13 sites in CA, CO, FL +7
What this study is about
Researchers are testing whether it drug, LY4052031, is safe and effective in people with advanced solid tumors. The trial will last up to approximately 4 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LY4052031
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1b: To assess the antitumor activity of LY4052031 Monotherapy: Overall response rate (ORR)
Secondary: To characterize the PK properties of LY4052031: Area under the concentration versus time curve (AUC), To characterize the pharmacokinetics (PK) properties of LY4052031: Minimum Plasma Concentration (Cmin), To evaluate the preliminary antitumor activity of LY4052031: Disease control rate (DCR), To evaluate the preliminary antitumor activity of LY4052031: Duration of response (DOR), To evaluate the preliminary antitumor activity of LY4052031: Overall response rate (ORR), To evaluate the preliminary antitumor activity of LY4052031: Overall survival (OS), To evaluate the preliminary antitumor activity of LY4052031: Progression free survival (PFS)
Oncology